Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis

Astrid Jüngel, Caroline Ospelt, Mark Lesch, Melissa Thiel, Teresa Sunyer, Olivier Schorr, Beat A. Michel, Renate E. Gay, Christoph Kolling, Craig Flory, Steffen Gay, Michel Neidhart

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To evaluate the decrease of cartilage destruction by a novel orally active and specific matrix metalloproteinase 13 (MMP-13) inhibitor in three different animal models of rheumatoid arthritis (RA). Materials and methods: The SCID mouse co-implantation model of RA, the collagen-induced arthritis (CIA) model in mice and the antigen-induced arthritis model (AIA) in rabbits were used. Results: In the SCID mouse co-implantation model, the MMP-13 inhibitor reduced cartilage destruction by 75%. In the CIA model of RA, the MMP-13 inhibitor resulted in a significant and dose-dependent decrease in clinical symptoms as well as of cartilage erosion by 38% (30 mg/kg), 28% (10 mg/kg) and 21% (3 mg/kg). No significant effects were seen in the AIA model. No toxic effects were seen in all three animal models. Conclusion: Although several MMPs in concert with other proteinases have a role in the process of cartilage destruction, there is a need for highly selective MMP inhibitors to reduce severe side effects that occur with non-specific inhibitors. Significant inhibition of MMP-13 reduced cartilage erosions in two of three tested animal models of RA. These results strongly support the development of this class of drugs to reduce or halt joint destruction in patients with RA.

Original languageEnglish (US)
Pages (from-to)898-902
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Matrix Metalloproteinase 13
Matrix Metalloproteinase Inhibitors
Cartilage
Rheumatoid Arthritis
Animals
Animal Models
Experimental Arthritis
SCID Mice
Arthritis
Antigens
Poisons
Matrix Metalloproteinases
Erosion
Peptide Hydrolases
Collagen
Joints
Rabbits
Pharmaceutical Preparations

Cite this

Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. / Jüngel, Astrid; Ospelt, Caroline; Lesch, Mark; Thiel, Melissa; Sunyer, Teresa; Schorr, Olivier; Michel, Beat A.; Gay, Renate E.; Kolling, Christoph; Flory, Craig; Gay, Steffen; Neidhart, Michel.

In: Annals of the Rheumatic Diseases, Vol. 69, No. 5, 01.05.2010, p. 898-902.

Research output: Contribution to journalArticle

Jüngel, A, Ospelt, C, Lesch, M, Thiel, M, Sunyer, T, Schorr, O, Michel, BA, Gay, RE, Kolling, C, Flory, C, Gay, S & Neidhart, M 2010, 'Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 898-902. https://doi.org/10.1136/ard.2008.106021
Jüngel, Astrid ; Ospelt, Caroline ; Lesch, Mark ; Thiel, Melissa ; Sunyer, Teresa ; Schorr, Olivier ; Michel, Beat A. ; Gay, Renate E. ; Kolling, Christoph ; Flory, Craig ; Gay, Steffen ; Neidhart, Michel. / Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. In: Annals of the Rheumatic Diseases. 2010 ; Vol. 69, No. 5. pp. 898-902.
@article{0fd935d5d72041f5a0f22fa67cd48549,
title = "Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis",
abstract = "Objective: To evaluate the decrease of cartilage destruction by a novel orally active and specific matrix metalloproteinase 13 (MMP-13) inhibitor in three different animal models of rheumatoid arthritis (RA). Materials and methods: The SCID mouse co-implantation model of RA, the collagen-induced arthritis (CIA) model in mice and the antigen-induced arthritis model (AIA) in rabbits were used. Results: In the SCID mouse co-implantation model, the MMP-13 inhibitor reduced cartilage destruction by 75{\%}. In the CIA model of RA, the MMP-13 inhibitor resulted in a significant and dose-dependent decrease in clinical symptoms as well as of cartilage erosion by 38{\%} (30 mg/kg), 28{\%} (10 mg/kg) and 21{\%} (3 mg/kg). No significant effects were seen in the AIA model. No toxic effects were seen in all three animal models. Conclusion: Although several MMPs in concert with other proteinases have a role in the process of cartilage destruction, there is a need for highly selective MMP inhibitors to reduce severe side effects that occur with non-specific inhibitors. Significant inhibition of MMP-13 reduced cartilage erosions in two of three tested animal models of RA. These results strongly support the development of this class of drugs to reduce or halt joint destruction in patients with RA.",
author = "Astrid J{\"u}ngel and Caroline Ospelt and Mark Lesch and Melissa Thiel and Teresa Sunyer and Olivier Schorr and Michel, {Beat A.} and Gay, {Renate E.} and Christoph Kolling and Craig Flory and Steffen Gay and Michel Neidhart",
year = "2010",
month = "5",
day = "1",
doi = "10.1136/ard.2008.106021",
language = "English (US)",
volume = "69",
pages = "898--902",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis

AU - Jüngel, Astrid

AU - Ospelt, Caroline

AU - Lesch, Mark

AU - Thiel, Melissa

AU - Sunyer, Teresa

AU - Schorr, Olivier

AU - Michel, Beat A.

AU - Gay, Renate E.

AU - Kolling, Christoph

AU - Flory, Craig

AU - Gay, Steffen

AU - Neidhart, Michel

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objective: To evaluate the decrease of cartilage destruction by a novel orally active and specific matrix metalloproteinase 13 (MMP-13) inhibitor in three different animal models of rheumatoid arthritis (RA). Materials and methods: The SCID mouse co-implantation model of RA, the collagen-induced arthritis (CIA) model in mice and the antigen-induced arthritis model (AIA) in rabbits were used. Results: In the SCID mouse co-implantation model, the MMP-13 inhibitor reduced cartilage destruction by 75%. In the CIA model of RA, the MMP-13 inhibitor resulted in a significant and dose-dependent decrease in clinical symptoms as well as of cartilage erosion by 38% (30 mg/kg), 28% (10 mg/kg) and 21% (3 mg/kg). No significant effects were seen in the AIA model. No toxic effects were seen in all three animal models. Conclusion: Although several MMPs in concert with other proteinases have a role in the process of cartilage destruction, there is a need for highly selective MMP inhibitors to reduce severe side effects that occur with non-specific inhibitors. Significant inhibition of MMP-13 reduced cartilage erosions in two of three tested animal models of RA. These results strongly support the development of this class of drugs to reduce or halt joint destruction in patients with RA.

AB - Objective: To evaluate the decrease of cartilage destruction by a novel orally active and specific matrix metalloproteinase 13 (MMP-13) inhibitor in three different animal models of rheumatoid arthritis (RA). Materials and methods: The SCID mouse co-implantation model of RA, the collagen-induced arthritis (CIA) model in mice and the antigen-induced arthritis model (AIA) in rabbits were used. Results: In the SCID mouse co-implantation model, the MMP-13 inhibitor reduced cartilage destruction by 75%. In the CIA model of RA, the MMP-13 inhibitor resulted in a significant and dose-dependent decrease in clinical symptoms as well as of cartilage erosion by 38% (30 mg/kg), 28% (10 mg/kg) and 21% (3 mg/kg). No significant effects were seen in the AIA model. No toxic effects were seen in all three animal models. Conclusion: Although several MMPs in concert with other proteinases have a role in the process of cartilage destruction, there is a need for highly selective MMP inhibitors to reduce severe side effects that occur with non-specific inhibitors. Significant inhibition of MMP-13 reduced cartilage erosions in two of three tested animal models of RA. These results strongly support the development of this class of drugs to reduce or halt joint destruction in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=77951586059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951586059&partnerID=8YFLogxK

U2 - 10.1136/ard.2008.106021

DO - 10.1136/ard.2008.106021

M3 - Article

C2 - 19497915

AN - SCOPUS:77951586059

VL - 69

SP - 898

EP - 902

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 5

ER -